Stock of the Day

July 31, 2023

Bristol Myers Squibb (BMY)

$48.06
+$1.37 (+2.9%)
Market Cap: $97.80B

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol Myers Squibb Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

  • The company recently reported strong earnings, with earnings per share (EPS) exceeding analysts' expectations, indicating robust financial performance.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and other serious diseases, which can drive future growth.
  • The current stock price is around $70, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • The company has a solid dividend yield of approximately 5.33%, providing a steady income stream for investors.
  • With a high return on equity of 87.62%, Bristol-Myers Squibb demonstrates effective management and profitability, which can be attractive to investors.

Bristol Myers Squibb Bear Case

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

  • The company's quarterly revenue was down about 5.6% compared to the same period last year, which may raise concerns about its growth trajectory.
  • With a dividend payout ratio of 92.88%, there may be limited room for future dividend increases, which could affect income-focused investors.
  • Recent product performance may be impacted by competition in the biopharmaceutical market, potentially affecting future sales and market share.
  • Investors should consider the risks associated with regulatory approvals and market acceptance of new treatments, which can be unpredictable.
  • Market volatility in the healthcare sector can lead to fluctuations in stock price, which may pose risks for investors looking for stability.
← Previous Stock of the DayNext Stock of the Day →

Recent News